<code id='D637D4A250'></code><style id='D637D4A250'></style>
    • <acronym id='D637D4A250'></acronym>
      <center id='D637D4A250'><center id='D637D4A250'><tfoot id='D637D4A250'></tfoot></center><abbr id='D637D4A250'><dir id='D637D4A250'><tfoot id='D637D4A250'></tfoot><noframes id='D637D4A250'>

    • <optgroup id='D637D4A250'><strike id='D637D4A250'><sup id='D637D4A250'></sup></strike><code id='D637D4A250'></code></optgroup>
        1. <b id='D637D4A250'><label id='D637D4A250'><select id='D637D4A250'><dt id='D637D4A250'><span id='D637D4A250'></span></dt></select></label></b><u id='D637D4A250'></u>
          <i id='D637D4A250'><strike id='D637D4A250'><tt id='D637D4A250'><pre id='D637D4A250'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:entertainment    Page View:27
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In